Risk-adapted postmastectomy radiotherapy based on local-regional recurrence for T1-2N1M0 breast Cancer]
M Li,S L Wang,H Fang,Y Tang,B Chen,S N Qi,Y W Song,Y P Liu,N N Lu,N Li,Y Tang,H Ren,J Jin,Y X Li
DOI: https://doi.org/10.3760/CMA.J.ISSN.0253-3766.2017.11.007
2017-01-01
Abstract:Objective: To establish a risk-adapted postmastectomy radiotherapy strategy based on local-regional recurrence for intermediate-risk breast cancer (T1~2N1M0 stage). Methods: A total of 2413 patients with T1-2N1M0 breast cancer were retrospectively reviewed. Of them, 588 patients (24.4%) received postmastectomy radiotherapy (PMRT), while 1 825 (75.6%) patients did not. A comprehensive comparative study was performed by using multivariable and propensity score-matched (PSM) analyses. Results: The median follow-up time was 67.0 months, the 5-year local region recurrence free-survival (LRRFS), disease-free survival (DFS) and overall survival (OS) were 93.8%, 85.7% and 93.3%, respectively. The 5-year local region recurrence (LRR) was 6.1%. For patients without PMRT, multivariable analysis indicated that age, tumor localization, molecular subtype, pathologic T stage and number of positive lymph node were independent factors for LRRFS (all of P<0.05). Patients with T1-2N1 breast cancer were classified into low-risk group (0-1 risk factor, 768 patients), intermediate-risk group (2 risk factors, 690 patients) and high-risk groups (≥3 risk factors, 544 patients) based on the five independent factors mentioned above. The 5-year LRRFS, DFS and OS were significantly different among the three groups (P<0.001). In low- and intermediate-risk groups, there were no significant differences in LRRFS, DFS and OS of patients who received PMRT or not (P>0.05). In high-risk group, the DFS of patients received PMRT or not were 79.8% and 74.4%, respectively (P=0.127), the OS of them were 86.8% and 87.1%, respectively (P=0.174), and the LRRFS were 93.3% and 84.3%, respectively (P=0.002). After PSM adjustment, no significant differences in LRRFS, DFS and OS were observed between PMRT-received subgroup and no PMRT subgroup of low-risk group (P>0.05). In intermediate-risk group, the LRRFS of patients received PMRT or not were 95.2% and 91.0%, respectively (P=0.037). However, in the high-risk group, the LRRFS, DFS and OS of patients received PMRT were 93.3%, 79.7% and 86.6%, respectively, while those of patients did not receive PMRT were 78.5% (P<0.001), 69.5% (P=0.038) and 85.7% (P=0.080), respectively. Conclusions: The local-regional recurrence risks of patients with pT1-2N1 breast cancer are viable and risk-adapted PMRT is available for them. Better prognoses can be achieved by the patients of intermediate and high-risk group. More samples on this subject are needed to validate the results.目的： 探讨早期中危(pT1～2N1M0期)乳腺癌根治术后局部区域复发风险分层和放疗选择。 方法： 2 413例pT1～2N1M0期乳腺癌患者中，根治术后放疗(PMRT) 588例(24.4%)，未接受PMRT 1 825例(75.6%)，应用多因素和倾向评分配比(PSM)分析进行综合比较研究。 结果： 全组患者中位随访时间为67.0个月，其5年无局部区域复发生存率(LRRFS)、无病生存率和总生存率分别为93.8%、85.7%和93.3%，5年局部区域复发率为6.1%。对未接受PMRT的1 825例患者进行局部区域复发风险分层，多因素分析显示，年龄、原发灶部位、分子分型、pT分期和阳性淋巴结数目是影响LRRFS的独立因素(均P<0.05)。以年龄、原发灶部位、分子分型、pT分期和阳性淋巴结数目5个高危因素进行分组，低危组(0～1个危险因素)768例，中危组(2个危险因素)690例，高危组(≥3个危险因素)544例，3组患者的5年LRRFS、无病生存率和总生存率差异均有统计学意义(P<0.001)。在低危组和中危组中，PMRT组和未接受PMRT组患者的5年LRRFS、无病生存率和总生存率差异均无统计学意义(均P>0.05)。在高危组中，PMRT组和未接受PMRT组患者的5年LRRFS分别为93.3%和84.3%(P＝0.002)，5年无病生存率分别为79.8%和74.4%(P＝0.127)，5年生存率分别为86.8%和87.1%(P＝0.174)。经过PSM调整，低危组中，PMRT组和未接受PMRT组患者的5年LRRFS、无病生存率和总生存率差异均无统计学意义(均P>0.05)。中危组中，PMRT组和未接受PMRT组患者的5年LRRFS分别为95.2%和91.0%(P＝0.037)。在高危组中，PMRT组患者的5年LRRFS、无病生存率和总生存率分别为93.3%、79.7%和86.6%，未接受PMRT组分别为78.5%、69.5%和85.7% (P<0.001，P＝0.038，P＝0.080)。 结论： pT1～2N1M0期乳腺癌患者根治术后具有不同的局部区域复发风险，基于风险分层的PMRT是可行的，中高危患者可能带来生存获益，但需要扩大样本量证实。.